Anticipated Spike in Deal Activity in 2021 Makes Customized R&W Insurance Critical, Finds Lowenstein Sandler

NEW YORK–(BUSINESS WIRE)–Encouraging news about COVID-19 vaccination trials and the impending resolution of the long election process bode well for deal activity in 2021, according to M&A and insurance recovery lawyers from Lowenstein Sandler. With an anticipated increase in financial transactions, competition among insurers is also expected to heat up, making this an ideal time … [Read more…]

ImmunityBio Simulates SARS-CoV-2 Spike Protein Binding Using Molecular Dynamics

Detailed computer modeling, completed in partnership with Microsoft, explains virulence of COVID-19 and provides key information that may lead to a better understanding of the multiple mutations currently occurring to the “spike” protein as the virus evolves Computer-based molecular dynamics simulation allows highly detailed visualization of free (unbound) spike receptor binding domain (S RBD) and … [Read more…]

Vicks® Donates $1 million for COVID-19 Health Care Relief

Humanitarian Aid Organization, Direct Relief, will use the funds to deliver protective gear and essential medical aid to health care organizations CINCINNATI–(BUSINESS WIRE)–In response to the novel coronavirus (COVID-19) pandemic, the Vicks® family of cold and flu brands – NyQuil™, DayQuil™ and VapoRub™ – will donate $1 million to Direct Relief, one of the world’s … [Read more…]

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™

The target Prescription Drug User Fee Act (PDUFA) action date for a decision by the FDA is May 2023 NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data support the safety and effectiveness of PAXLOVID™ (nirmatrelvir … [Read more…]

Rapid Dose Therapeutics Reports Fiscal Year 2022 Financial Results

BURLINGTON, Ontario–(BUSINESS WIRE)–On Friday, January 27, 2023, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), filed its financial results for the fiscal year ended February 28, 2022. Now that the Company has completed the filing of its audited financial statements for the fiscal year ended February 28, 2022 as well as its interim … [Read more…]

$82 Billion Global Vaccines Market 2023 to 2029: Growth Trends, and Market Forecasts –

DUBLIN–(BUSINESS WIRE)–The “Vaccines Market – Global Industry Analysis (2019 – 2021), Growth Trends, and Market Forecast (2023 – 2029)” report has been added to’s offering. Escalating investments by vaccine manufacturers, and governments from across the globe is predominantly driving the global vaccines market growth. This US$90 Bn market (2021) is projected to reach the … [Read more…]

Tevogen Bio CEO Ryan Saadi and CSO Neal Flomenberg share White House concerns about emerging COVID-19 variants and impact on immunocompromised patients, and express commitment to accelerate development of company’s investigational COVID-19 therapy

Tevogen Bio CEO and CSO share concerns of the White House and President Joe Biden who stated, “New variants may make some existing protections ineffective for the immunocompromised” and promise to do everything in their power to accelerate development and manufacturing of its investigational therapy, TVGN-489 A comprehensive review by the company’s R&D team found … [Read more…]

Global Preclinical Medical Device Testing Services Market (2022 to 2030) – Size, Share & Trends Analysis Report –

DUBLIN–(BUSINESS WIRE)–The “Preclinical Medical Device Testing Services Market by Service (Biocompatibility Tests, Chemistry Test, Microbiology & Sterility Testing, Package Validation), by Region, and Segment Forecasts, 2022-2030” report has been added to’s offering. The global preclinical medical device testing services market share is expected to reach USD 4.9 billion by 2030, according to this report. … [Read more…]

Entos Pharmaceuticals Passes Significant Enrollment Milestone in Phase 2 Clinical Trial of its COVID-19 DNA Vaccine

This phase 2 trial evaluates the safety, tolerability, and immunogenicity of Covigenix VAX-001-1b in healthy adults 18 years and older A total of 268 participants have been enrolled in the study at two sites in Burkina Faso, completing the single and two-dose cohorts EDMONTON, Alberta & OUAGADOUGOU, Burkina Faso–(BUSINESS WIRE)–Entos Pharmaceuticals (Entos), a clinical-stage biotechnology … [Read more…]

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of … [Read more…]